Substance Use Disorders Clinical Trial
| NCT number | NCT01085188 |
| Other study ID # | 1018-1201 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 3 |
| First received | March 10, 2010 |
| Last updated | March 10, 2010 |
| Start date | January 2003 |
| Verified date | March 2010 |
| Source | Chestnut Health Systems |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Institutional Review Board |
| Study type | Interventional |
Following discharge from residential treatment 324 adolescents are randomly assigned to Assertive Continuing Care with and without motivational incentives in a 2 x 2 factorial design. Clinical outcomes are assessed at 3, 6, 9, and 12 months post discharge.
| Status | Completed |
| Enrollment | 342 |
| Est. completion date | |
| Est. primary completion date | January 2008 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 12 Years to 18 Years |
| Eligibility |
Inclusion Criteria: - Met DSM-IV diagnostic criteria for abuse or dependence on alcohol or another drug in the past year - Been between the ages of 12 and 18 at the time of residential admission; and (c) resided in one of ten Illinois counties targeted for the intervention Exclusion Criteria: - left residential treatment prior to the seventh day - did not return to a target county at discharge - showed evidence of cognitive impairment that interfered with understanding of study instruments, procedures, or the informed consent process - were deemed dangerous to themselves or others during treatment - were a ward of child protective services and inaccessible for the intervention - met DSM-IV criteria for pathological gambling - were discharged to the state department of corrections - were already participating in a treatment study |
Allocation: Randomized, Intervention Model: Factorial Assignment, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Chestnut Health Systems | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05660434 -
Using Aromatherapy in Substance Use Disorder
|
N/A | |
| Active, not recruiting |
NCT05338268 -
Substance Use and Loneliness
|
N/A | |
| Completed |
NCT04098614 -
Barriers to Substance Use Disorder Recovery
|
N/A | |
| Completed |
NCT03954184 -
E-health Implementation (Iowa)
|
N/A | |
| Completed |
NCT03590106 -
Cardiac Surgery Peer Recovery Support Program
|
N/A | |
| Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
| Recruiting |
NCT06273228 -
Parenting Young Children in Pediatrics
|
N/A | |
| Recruiting |
NCT05327504 -
Written Exposure Therapy for Veterans With SUD and PTSD
|
N/A | |
| Terminated |
NCT03517111 -
The Impact of a Parenting Intervention on Latino Youth Health Behaviors
|
N/A | |
| Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
| Completed |
NCT04401215 -
Technologically-Augmented Referrals to Mitigate Addiction Consequences
|
N/A | |
| Not yet recruiting |
NCT06187701 -
Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients
|
N/A | |
| Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A | |
| Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
| Active, not recruiting |
NCT02382042 -
Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans
|
N/A | |
| Completed |
NCT01237366 -
Study Targeting Affect Regulation
|
Phase 1/Phase 2 | |
| Terminated |
NCT01356667 -
Drum-Assisted Therapy for Native Americans
|
N/A | |
| Completed |
NCT00708890 -
Twelve Step Based Self-help Groups for Substance Related Disorders
|
N/A | |
| Active, not recruiting |
NCT04048850 -
Zepatier in Patients With Substance Use
|
||
| Recruiting |
NCT05976646 -
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
|
Phase 1/Phase 2 |